hydrOXYchloroQUINE Sulphate
25 mg/mL Oral Suspension
(contains 19.4 mg base/mL)

Batch No: ____________________________

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Mfr</th>
<th>Lot #</th>
<th>Expiry Date</th>
<th>Quantity</th>
<th>Measured</th>
<th>Checked</th>
</tr>
</thead>
<tbody>
<tr>
<td>hydroxychloroquine sulphate</td>
<td>Mylan/APO</td>
<td></td>
<td></td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>200 mg tablets</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORAL-MIX</td>
<td>Medisca</td>
<td></td>
<td></td>
<td>q.s. 80 mL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional Information:

Equipment:
mortar and pestle              glass stirring rod
graduated measure

Procedure:

Follow your Dept. procedures for risk assessment/training/PPE/equipment/facilities/NAPRA level

1. Soak tablets in small amount of vehicle in the mortar for a minimum of 30 minutes on the counter.
2. Use pestle to levigate into a smooth paste. Continue to levigate as vehicle is added in small amounts until a liquid is formed.
3. Transfer liquid contents from mortar to graduate.
4. Use a small amount of vehicle to rinse mortar and add it to graduate.
5. Use vehicle to q.s. to the final volume. Stir well.
6. Transfer to amber bottle and label.

Quality Control:

Expected Product Appearance | Additional Notes
--- | ---
White suspension | Black dots from tablet engraving present, disappears over time

Storage: Room temperature
Packaging: Amber glass/plastic PET bottles
BUD: 60 days

Sample Label:

hydrOXYchloroQUINE Sulphate 25 mg/mL Oral Suspension
(contains 19.4 mg base/mL)

Lot: BUD:

Room Temperature Shake Well

Date Made/Prepared By/Checked By: ________________________________

Reference:

1. McHenry AR et al. Stability of Extemporaneously prepared Hydroxychloroquine sulfate 25mg/mL suspensions in plastic bottles and syringes. IJPC May/June 2017;21 (3):251-253

Formulation Reviewed: October, 2020

Disclaimer: The information in this compounding and preparation worksheet was developed for in-house use only by The Hospital for Sick Children (“SickKids”) and its staff. While SickKids endeavours to keep this information up to date and accurate, patient circumstances will vary and some information may become outdated as a result of recent medical developments following the time of printing. Any reliance you place on such information is therefore strictly at your own risk. Please note that the doses provided do not necessarily conform to the manufacturer’s recommendations, and formulary drugs may not be licensed for use in children. The reader is cautioned to check the product information sheet provided by the manufacturer, and to verify indications, contraindications and recommended dosages. SickKids make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, or suitability of the information and related products contained in this worksheet for any purpose. SickKids accepts no responsibility for the reader’s use, misuse or misinterpretation of the information, and does not promise success in achieving any desired result. In no event will SickKids be liable for any damage, liability or loss or for any indirect, incidental or consequential damages arising from the use of this information.